Artist Natalia Padilla, founder of Dsgn For Us, poses for a photo with her project, “YELLOW,” an interactive paper installation, at Arts Mission in Oak Cliff, Thursday, March 21, 2024.

Design Therapeutics, Inc. (DSGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Design Therapeutics Inc (NASDAQ:DSGN) announces Q3 2023 financial results with a net loss of $15.8 million.DSGN's cash reserves of approximately $290 million expected to support operations through ...

Design Therapeutics to Participate in 2025 RBC Capital Markets Healthcare Conference. CARLSBAD, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage ...

Attendee Yumna Moazzam of Dallas creates her artwork at “YELLOW,” an interactive paper installation, by Dsgn For Us, at Arts Mission in Oak Cliff, Thursday, March 21, 2024.